| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3353994 | Immunity | 2008 | 5 Pages |
Abstract
In 2006, a clinical trial with the CD28 superagonistic antibody TGN1412 in London turned into a catastrophe. Studies are beginning to unravel the difference between the human and preclinical animal response to the antibody.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Burkhart Schraven, Ulrich Kalinke,